{"title":"循环肿瘤DNA在膀胱癌预后诊断中的价值：系统回顾和荟萃分析。","authors":"Yu Lu, Huajun Wu, Jian Jiang, Siwen Bao, Chen Ling","doi":"10.1159/000546014","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to systematically evaluate the clinical efficacy of ctDNA in the prognostic assessment of bladder cancer, and to provide a basis for its application in individualized treatment and risk stratification management.</p><p><strong>Methods: </strong>Studies related to ctDNA in prognostic assessment of bladder cancer were screened by systematically searching PubMed, Cochrane Library, Web of Science, Willey library, CNKI and other databases, and the search was from inception to December 2024, and the data were extracted and analyzed by Meta-analysis. A random-effects model was used to calculate SEN, SPE, PLR, NLR, DOR, and AUC, and the heterogeneity among studies and publication bias were also assessed.</p><p><strong>Results: </strong>A total of 9 papers were included, and the results showed that ctDNA testing had a SEN of 0.68 (95% CI: 0.54-0.78), SPE of 0.76 (95% CI: 0.51-0.90), and an AUC of 0.75 (95% CI: 0.71-0.79), suggesting that it has a moderate level of diagnostic efficacy in the assessment of prognosis in bladder cancer. PLR and NLR were 2.8 (95% CI: 1.24-6.35) and 0.43 (95% CI: 0.28-0.65), respectively, with a DOR of 6.56 (95% CI: 2.12-20.33).Fagan plot analysis showed that the posterior probability of a positive result rose to 74% and the posterior probability of a negative result decreased to 30% when the prior probability was 50%. Deeks funnel plot analysis showed no significant publication bias (P=0.24). However, inter-study heterogeneity was high (all I² values >80%), which may have been influenced by factors such as assay technique, patient characteristics, and follow-up time.</p><p><strong>Conclusion: </strong>ctDNA demonstrates some clinical application value in the prognostic assessment of bladder cancer, and can assist in predicting patient recurrence and survival. However, its independent predictive efficacy is not enough to replace traditional assessment methods. Future studies should aim to optimize the detection technology, unify the study design, expand the sample size, and combine multi-omics data for joint analysis, in order to further improve its potential application in the prognostic assessment of bladder cancer.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-17"},"PeriodicalIF":1.5000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The value of circulating tumor DNA in the prognostic diagnosis of bladder cancer: a systematic review and meta-analysis.\",\"authors\":\"Yu Lu, Huajun Wu, Jian Jiang, Siwen Bao, Chen Ling\",\"doi\":\"10.1159/000546014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The aim of this study was to systematically evaluate the clinical efficacy of ctDNA in the prognostic assessment of bladder cancer, and to provide a basis for its application in individualized treatment and risk stratification management.</p><p><strong>Methods: </strong>Studies related to ctDNA in prognostic assessment of bladder cancer were screened by systematically searching PubMed, Cochrane Library, Web of Science, Willey library, CNKI and other databases, and the search was from inception to December 2024, and the data were extracted and analyzed by Meta-analysis. A random-effects model was used to calculate SEN, SPE, PLR, NLR, DOR, and AUC, and the heterogeneity among studies and publication bias were also assessed.</p><p><strong>Results: </strong>A total of 9 papers were included, and the results showed that ctDNA testing had a SEN of 0.68 (95% CI: 0.54-0.78), SPE of 0.76 (95% CI: 0.51-0.90), and an AUC of 0.75 (95% CI: 0.71-0.79), suggesting that it has a moderate level of diagnostic efficacy in the assessment of prognosis in bladder cancer. PLR and NLR were 2.8 (95% CI: 1.24-6.35) and 0.43 (95% CI: 0.28-0.65), respectively, with a DOR of 6.56 (95% CI: 2.12-20.33).Fagan plot analysis showed that the posterior probability of a positive result rose to 74% and the posterior probability of a negative result decreased to 30% when the prior probability was 50%. Deeks funnel plot analysis showed no significant publication bias (P=0.24). However, inter-study heterogeneity was high (all I² values >80%), which may have been influenced by factors such as assay technique, patient characteristics, and follow-up time.</p><p><strong>Conclusion: </strong>ctDNA demonstrates some clinical application value in the prognostic assessment of bladder cancer, and can assist in predicting patient recurrence and survival. However, its independent predictive efficacy is not enough to replace traditional assessment methods. Future studies should aim to optimize the detection technology, unify the study design, expand the sample size, and combine multi-omics data for joint analysis, in order to further improve its potential application in the prognostic assessment of bladder cancer.</p>\",\"PeriodicalId\":23414,\"journal\":{\"name\":\"Urologia Internationalis\",\"volume\":\" \",\"pages\":\"1-17\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologia Internationalis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000546014\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Internationalis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546014","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
The value of circulating tumor DNA in the prognostic diagnosis of bladder cancer: a systematic review and meta-analysis.
Objective: The aim of this study was to systematically evaluate the clinical efficacy of ctDNA in the prognostic assessment of bladder cancer, and to provide a basis for its application in individualized treatment and risk stratification management.
Methods: Studies related to ctDNA in prognostic assessment of bladder cancer were screened by systematically searching PubMed, Cochrane Library, Web of Science, Willey library, CNKI and other databases, and the search was from inception to December 2024, and the data were extracted and analyzed by Meta-analysis. A random-effects model was used to calculate SEN, SPE, PLR, NLR, DOR, and AUC, and the heterogeneity among studies and publication bias were also assessed.
Results: A total of 9 papers were included, and the results showed that ctDNA testing had a SEN of 0.68 (95% CI: 0.54-0.78), SPE of 0.76 (95% CI: 0.51-0.90), and an AUC of 0.75 (95% CI: 0.71-0.79), suggesting that it has a moderate level of diagnostic efficacy in the assessment of prognosis in bladder cancer. PLR and NLR were 2.8 (95% CI: 1.24-6.35) and 0.43 (95% CI: 0.28-0.65), respectively, with a DOR of 6.56 (95% CI: 2.12-20.33).Fagan plot analysis showed that the posterior probability of a positive result rose to 74% and the posterior probability of a negative result decreased to 30% when the prior probability was 50%. Deeks funnel plot analysis showed no significant publication bias (P=0.24). However, inter-study heterogeneity was high (all I² values >80%), which may have been influenced by factors such as assay technique, patient characteristics, and follow-up time.
Conclusion: ctDNA demonstrates some clinical application value in the prognostic assessment of bladder cancer, and can assist in predicting patient recurrence and survival. However, its independent predictive efficacy is not enough to replace traditional assessment methods. Future studies should aim to optimize the detection technology, unify the study design, expand the sample size, and combine multi-omics data for joint analysis, in order to further improve its potential application in the prognostic assessment of bladder cancer.
期刊介绍：
Concise but fully substantiated international reports of clinically oriented research into science and current management of urogenital disorders form the nucleus of original as well as basic research papers. These are supplemented by up-to-date reviews by international experts on the state-of-the-art of key topics of clinical urological practice. Essential topics receiving regular coverage include the introduction of new techniques and instrumentation as well as the evaluation of new functional tests and diagnostic methods. Special attention is given to advances in surgical techniques and clinical oncology. The regular publication of selected case reports represents the great variation in urological disease and illustrates treatment solutions in singular cases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
